The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma

Among patients with previously untreated DLBCL, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone demonstrated a prolonged progression-free survival, compared with standard care R-CHOP, after a median follow-up of 28.2 months (HR 0.73; 95% CI: 0.57-0.95; p<0.02). This data from the phase 3 POLARIX trial was presented during the 2021 ASH Annual Meeting.